Literature DB >> 26478796

Recurrence and Five -Year Survival in Colorectal Cancer Patients After Surgery.

Seyed Reza Fatemi1, Mohamad Amin Pourhoseingholi1, Farshad Asadi1, Mohsen Vahedi2, Sara Pasha1, Leila Alizadeh1, Mohammad Reza Zali1.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is a common malignancyworldwide and its outcome is most closely related to the extent of disease at presentation. Early diagnosis of an asymptomatic recurrence increases the likelihood of a complete surgical resection.
OBJECTIVES: The aim of this study was to evaluate the incidence of colorectal cancer recurrence and survival rate within 5 years, after surgery. PATIENTS AND METHODS: During the 9-year period since 21st Mar, 2004 to 20th Mar, 2013, patients whose primary colorectal cancer were resected in Taleghani hospital, Tehran, Iran were selected in a historical cohort. The necessary data such as demographic, age, gender, family history of CRC, site and size of tumor, stage of tumor, operation details, histological results, treatment method, histopathologic, etc. were collected. Then the recurrence and survival of colorectal cancer within 5 years after operation and their risk factors were evaluated. P value less than 0.05 were considered significant. All analysis was done using SPSS software.
RESULTS: A total of 107 patients underwent resection for colorectal cancer during the study period, with mean age of 53.50 ± 12.68 years (range 24 - 76 years), survival rate of 73.8% (rectum 70.0% and colon 75.9%), and mean survival time of 142.17 ± 21.60 month. The recurrence rate of CRC patients, during five years after surgery was 5.7%. Regional lymph nodes, Distance metastasis and Adjuvant therapy were significant prognosis factors of survival after surgery.
CONCLUSIONS: The rate of recurrence in Iranian patients was low, which could be due to improvement of exactness and expertise of surgeons or better adjuvant therapy. The significant association between survival and adjuvant therapy clarifies this finding. Early diagnosis and primary detection could increase the rate of survival.

Entities:  

Keywords:  Colorectal Cancer; Recurrence; Surgical Resection; Survival

Year:  2015        PMID: 26478796      PMCID: PMC4606369          DOI: 10.17795/ijcp.3439

Source DB:  PubMed          Journal:  Iran J Cancer Prev        ISSN: 2008-2398


1. Background

Colorectal cancer (CRC) is a common cancer worldwide (1). This malignancy is a public health burden in most industrialized countries and a most common cause of cancer-related deaths in the world (2). The incidence and mortality rate of this cancer is increasing in Iran and it is predicted that Iranian population may be experiencing an acceleration of its burden in future (3-5). A surgical resection is the only curative modality for localized colon cancer. It is the primary treatment modality for CRC, and outcome is most closely related to the extent of disease at presentation. The location of the primary tumor may also have prognostic significance. For each stage, cancers arising at or below the peritoneal reflection (rectosigmoid and rectum) have a worse five-year survival rate than those arising more proximally (6). Furthermore, within the rectum, distal cancers have a worse prognosis than more proximal lesions. Over the last 50 years, a gradual shift toward right-sided or proximal colon cancers has been observed (5). The survival rates of CRC vary throughout the world due to quality of care, including surgical techniques, which is a predictor of outcomes for local recurrence and cure rates (7, 8). CRC that has metastasized, or spread, to the regional lymph nodes carries a worse prognosis and a higher risk for recurrence. Studies showed that 15 to 30 percent of patients diagnosed with node-negative colorectal cancer experience disease recurrence within 2 - 5 years (9, 10). This high recurrence rate and a higher incidence of colorectal cancer in subjects at high risk of being CRC, highlights a healthcare opportunity for surveillance or interventions to reduce the morbidity associated with CRC (11).

2. Objectives

The aim of this study was to evaluate the incidence of colorectal cancer recurrence and survival rate within 5 years, after being affected by this cancer, with considering the effects of other clinical and demographic factors.

3. Patients and Methods

This was a historical cohort study in which all patients whose primary colorectal cancer were resected only by the one expert staff of colorectal surgeon or under his supervision and registered in the Taleghani Hospital, Tehran, since 21st Mar, 2004 to 20th Mar, 2013 entered to the study. The necessary data such as demographic, age, gender, family history of CRC, site and size of tumor, stage of tumor, operation details, histological results, treatment method, etc. had been extracted from medical records. All patients were followed for prognosis, mortality status and recurrence after the surgery (by repeated periodic visits, colonoscopy and telephone contact). Survival time was calculated from the date of surgery registration until death or the end of the study. Due to protocol of CRC management, for patients with stages II-III and some symptomatic stage IV, a colectomy (surgical removal of the tumor and regional lymph nodes and nearby tissues) were done and then chemotherapy based on 5-fluorouracil was offered to patients younger than 75 years with stage III or IV colon cancer or complicated stage II. Postoperative chemoradiation was offered only to those with stage II or stage III of rectosigmoid cancer when the local clearance was in doubt and preoperative chemoradiation was given to those with fixed T4 lesions. Chi-square test and Kaplan–Meier analysis have been done to find the prognosis factors, associated to survival and recurrence. P values of less than 0.05 were considered statistically significant. All analysis carried out, using SPSS software, version 17.

4. Results

A total of 107 patients (51.2% men) who underwent resection for colorectal cancer during the study period, entered to this study. 23.4% of patients had positive family history of CRC, and 53.8% were sporadic CRC. The mean age was 53.50 ± 12.68 years (range 24 - 76 years), and the survival rate was 73.8% with mean survival time of 142.17 ± 21.60 month. The recurrence rate after surgery was 5.7% and all of them were alive till the end of study. The mean duration of recurrence after surgery was 3.50 ± 1.23 years. Region of recurrences were: five patients (83.3%) near to site of anastomosis or previous tumor and one patient exactly at site of anastomosis. The demographic and clinicopathological factors associated with survival time after surgery were presented in Tables 1 and 2. According to log-rank test, Regional lymph nodes, Distance metastasis and Adjuvant therapy were the prognosis factors of survival in CRC patients after surgery, respectively. Patients with N1 regional LN, M0 level of metastasis and Adjuvant therapy had higher survival. Also, there was no significant association between type of surgery and risk of death in patients under study (Table 3).
Table 1.

Demographic Factors and Five Years Survival After Surgery in Colorectal Cancer Patients

VariablesNo. (%) of DeathSurvival Time/Std. Error, MoP Value
Gender 0.672
Male15 (27.3)84.20/7.79
Female13 (25.0)161.32/20.49
Age, y 0.176
≤ 5010 (23.2)151.29/25.29
> 5018 (28.1)7.98/5.44
Family history 0.555
Negative22 (26.8)149.42/17.51
Positive6 (24.0)84.55/8.47
BMI, kg/m 2 0.474
18.6 - 24.918 (30.0)125.42/25.66
25 - 29.98 (20.5)82.65/6.72
Category of CRC 0.646
≥ 302 (25.0)78.13/13.40
Sporadic12 (26.1)62.19/5.13
HNPCC15 (26.3)148.14/23.97
FAP1 (33.3)29.00/0.00
Table 2.

Clinicopathological Factors and Five Years Survival After Surgery in Colorectal Cancer Patients

VariablesNo. (%) of DeathSurvival Time/Std. Error, MoP Value
Histology 0.306
Adenocarcinoma26 (25.2)144.84/22.02
Others2 (50.0)41.62/9.19
Primary tumor site 0.289
Rt. colon8 (34.8)129.43/30.09
Lt. colon20 (24.7)88.14/6.41
Regional LN 0.023
N09 (16.7)95.29/7.58
N112 (40.0)125.19/24.80
N26 (40.0)59.54/12.50
Distant metastasis < 0.001
Mx2 (11.7)75.03/5.90
M018 (25.3)143.78/22.95
M18 (66.73)36.77/10.77
Grade of tumor 0.215
Well diff10 (18.2)178.21/19.56
Moderate diff10 (38.5)78.49/9.92
Poor diff3 (30.0)60.01/17.24
Radiotherapy 0.782
No19 (27.19)157.19/ 17.10
Yes7 (21.9)83.74/ 7.91
Neoadjuvant 0.436
No24 (28.6)138.31/ 21.79
Yes2 (12.5)84.10/10.28
Adjuvant therapy 0.018
No11 (36.7)58.32/8.47
Yes15 (21.4)157.64/24.45
Table 3.

Type of Surgery and Mortality, After Surgery in Colorectal Cancer Patients

Type of SurgeryNo (%) of DeathP Value
Partial colectomy 14 (23.0)0.643
Total colectomy 3 (37.5)0.643
Other techniques 6 (22.2)0.643
The demographic and clinicopathological factors associated with risk of recurrence are presented in Tables 4 and 5. According to the results, none of the demographic and clinicopathological factors was significantly associated with recurrence after surgery.
Table 4.

Demographic Factors and Recurrence After Surgery in Colorectal Cancer Patients

VariablesNo. (%) of RecurrenceP Value
Gender 0.357
Male4 (7.4)
Female2 (3.8)
Age, y 0.532
≤ 502 (4.7)
> 504 (6.3)
Family history 0.434
Negative4 (4.9)
Positive2 (8.0)
BMI, kg/m 2 0.274
18.6 - 24.92 (3.4)
25 - 29.94 (10.3)
≥ 300 (0.0)
Category of CRC 0.870
Sporadic3 (6.7)
HNPCC3 (5.3)
FAP0 (0.0)
Table 5.

Clinicopathological Factors and Recurrence after Surgery in Colorectal Cancer Patients

VariablesNo (%) of RecurrenceP Value
Histology 0.617
Adenocarcinoma6 (5.9)
Other histology0 (0.0)
Primary tumor site 0.621
Rt. colon1 (4.5)
Lt. colon5 (6.2)
Size of tumor, cm 0.917
< 10 (0.0)
1 - 54 (5.5)
> 51 (4.2)
Depth of tumor 0.846
T10 (0.0)
T21 (4.0)
T33 (5.2)
T40 (0.0)
Regional LN 0.616
N03 (5.6)
N11 (3.4)
N20 (0.0)
Distant metastases 0.717
Mx1 (5.9)
M03 (4.3)
M10 (0.0)
Grade of tumor 0.326
Well diff5 (9.1)
Moderate diff0 (0.0)
Poor diff0 (0.0)
Undifferentiated0 (0.0)
Radiotherapy 0.509
No3 (4.3)
Yes2 (6.3)
Neoadjuvant therapy 0.183
No3 (3.6)
Yes2 (12.5)
Adjuvant therapy 0.520
No1 (3.3)
Yes4 (5.8)
Type of surgery 0.281
Partial colectomy2 (3.7)
Total colectomy0 (0.0)
Other techniques3 (11.5)

5. Discussion

This study revealed that, in patients who underwent resection for colorectal cancer, the survival rate is high and the recurrence rate was just 5.7%. The evaluation of post-surgical survival of colorectal cancer is necessary due to comparing results together and then reevaluates cause of differences (kind of surgery, experience of surgeons, doing chemotherapy or chemo radiotherapy and its regimens, quality of post-surgical care and surveillance). There was no correlation between BMI and CRC survival in this study, which is different from many similar previous researches (12, 13). No age and gender relationship were observed with survival of CRC patients in this study, however some Iranian studies indicated that colorectal cancer occurs at a younger age (14). No patients in recurrence group faced death till the end of study. This statistics is better than other sites in Iran and other countries (15, 16), and similar to some Asian studies (17), which could be due to improvement of exactness and expertise of surgeon or better adjuvant therapy or difference stages in the patients who were operated. The significant association between survival and adjuvant therapy clarifies this finding too. However, the effectiveness of these treatments in the lower stages needs to be evaluated. The number of examined lymph nodes and Distance metastasis statistically predicted the survival, which is similar to study that indicated the risk of death was higher in patients with distant metastasis (18). Tumor size, grade of tumor and some other clinical factors were not associated to survival, which is in contrast to western studies (19). The incidence of CRC is lower in Iran compared to Western countries; however, its burden has been increasing in recent years (20, 21). In addition, five year survival rate of CRC has been reported to be lower than the world (22, 23). It seems that among the prognostic factors explored so far, the most important are those that relate to early diagnosis of cancer. So, primary detection is feasible since efficient screening modalities are available (24). Due to limited data about survival and recurrence of colorectal cancer after surgery and its risk factors in different areas of Iran, our study would be helpful to improving surveillance (pre and post-surgical), survival and recurrence of CRC and at least better managements and control of its risk factors. The evaluation of incidence and duration of colorectal cancer recurrence (where site, stage at time of presentation and site of recurrence) could conduct us to the better planning of post-surgical follow up, reevaluation of kind of surgery, adjuvant and neoadjuvant chemotherapy and chemoradiotherapy, in order to increase the survival of patients. The limitation of this study is low sample size of patients who underwent resection for colorectal cancer. So in some survival comparison, the results were not significant. It needs to conduct multicenter study in order to merge the patient’s dataset and increase reliability of results for future researches in Iran.
  20 in total

1.  Is there a true "shift" to the right colon in the incidence of colorectal cancer?

Authors:  Linda Rabeneck; Jessica A Davila; Hashem B El-Serag
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

2.  Fifty years of cancer incidence: CI5 I-IX.

Authors:  D Max Parkin; Jacques Ferlay; Maria-Paula Curado; Freddie Bray; Brenda Edwards; Hai-Rim Shin; David Forman
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

3.  Anastomotic leak increases distant recurrence and long-term mortality after curative resection for colonic cancer: a nationwide cohort study.

Authors:  Peter-Martin Krarup; Andreas Nordholm-Carstensen; Lars N Jorgensen; Henrik Harling
Journal:  Ann Surg       Date:  2014-05       Impact factor: 12.969

4.  Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients.

Authors:  Wai Lun Law; Kin Wah Chu
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

5.  Colorectal cancer in Iran: an epidemiological study.

Authors:  Safaee Azadeh; B Moghimi-Dehkordi; S R Fatem; M A Pourhoseingholi; S Ghiasi; M R Zali
Journal:  Asian Pac J Cancer Prev       Date:  2008 Jan-Mar

6.  DNA ploidy, tumour site, and prognosis in colorectal cancer. A flow cytometric study of paraffin-embedded tissue.

Authors:  T B Halvorsen; E Johannesen
Journal:  Scand J Gastroenterol       Date:  1990-02       Impact factor: 2.423

7.  Predictors of Colorectal Cancer Survival in Golestan, Iran: A Population-based Study.

Authors:  Mohammad Aryaie; Gholamreza Roshandel; Shahryar Semnani; Mohsen Asadi-Lari; Mohsen Aarabi; Mohammad Ali Vakili; Vahideh Kazemnejhad; Seyed Mehdi Sedaghat; Masoud Solaymani-Dodaran
Journal:  Epidemiol Health       Date:  2013-06-20

8.  Body weight and colorectal cancer risk in a cohort of Swedish women: relation varies by age and cancer site.

Authors:  P Terry; E Giovannucci; L Bergkvist; L Holmberg; A Wolk
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

Review 9.  Neoadjuvant chemotherapy followed by surgery versus surgery alone for colorectal cancer: meta-analysis of randomized controlled trials.

Authors:  Lei Huang; Tuan-Jie Li; Jian-Wen Zhang; Sha Liu; Bin-Sheng Fu; Wei Liu
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

10.  Health-related quality of life and risk of colorectal cancer recurrence and All-cause death among advanced stages of colorectal cancer 1-year after diagnosis.

Authors:  Carlos K H Wong; Wai-Lun Law; Yuk-Fai Wan; Jensen Tung-Chung Poon; Cindy Lo-Kuen Lam
Journal:  BMC Cancer       Date:  2014-05-17       Impact factor: 4.430

View more
  16 in total

1.  Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy.

Authors:  N Mejri; M Dridi; S Labidi; H El Benna; N Daoud; H Boussen
Journal:  Clin Transl Oncol       Date:  2017-06-06       Impact factor: 3.405

2.  Prognostic Factors of Rectal Cancer in Southern Iran.

Authors:  Seyed Vahid Hosseini; Abbas Rezaianzadeh; Salar Rahimikazerooni; Alimohammad Bananzadeh; Afrouz Farghadin; Mohammad Zare Band Amiry; Ahmad Izadpanah; Mohammad Mohammadianpanah; Sohrab Iranpour
Journal:  J Gastrointest Cancer       Date:  2020-11-19

3.  Evaluation of demographic, pathologic, and clinical characteristics and overall survival of patients with colon cancer in Northern Iran (Mazandaran Province) during 2012-2019.

Authors:  Elahe Rahimi; Jamshid Yazdani Charati; Rezaaali Mohammad Pour Tahamtan; Iradj Maleki
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

4.  Prognostic value of p53 mutation for poor outcome of Asian primary liver cancer patients: evidence from a cohort study and meta-analysis of 988 patients.

Authors:  Xiajie Wen; Fengmin Lu; Shuang Liu
Journal:  Onco Targets Ther       Date:  2016-12-08       Impact factor: 4.147

5.  Risk Factors Predicting Colorectal Cancer Recurrence Following Initial Treatment: A 5-year Cohort Study

Authors:  Mohammad Zare-Bandamiri; Mohammad Fararouei; Shadi Zohourinia; Nima Daneshi; Mostafa Dianatinasab
Journal:  Asian Pac J Cancer Prev       Date:  2017-09-27

6.  Identification of the anticancer effects of a novel proteasome inhibitor, ixazomib, on colorectal cancer using a combined method of microarray and bioinformatics analysis.

Authors:  Qiaowei Fan; Bingrong Liu
Journal:  Onco Targets Ther       Date:  2017-07-19       Impact factor: 4.147

7.  Proteomic Profiling of Colon Cancer Tissues: Discovery of New Candidate Biomarkers.

Authors:  Miriam Buttacavoli; Nadia Ninfa Albanese; Elena Roz; Ida Pucci-Minafra; Salvatore Feo; Patrizia Cancemi
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

8.  Treatment Outcomes of Patients With Colorectal Cancer Enrolled in a Comprehensive Benefits Program of the National Insurance System in the Philippines: Data From the Pilot Site.

Authors:  Frederic Ivan L Ting; Danielle Benedict L Sacdalan; Mayou Martin T Tampo; Rosielyn T Apellido; Hermogenes J Monroy; Marie Dione P Sacdalan; Dennis L Sacdalan
Journal:  JCO Glob Oncol       Date:  2020-02

9.  An effective cytokine adjuvant vaccine induces autologous T-cell response against colon cancer in an animal model.

Authors:  Huanyu Ju; Wenjing Xing; Jinfeng Yang; Yang Zheng; Xiuzhi Jia; Benning Zhang; Huan Ren
Journal:  BMC Immunol       Date:  2016-09-26       Impact factor: 3.615

10.  Familial Colorectal Cancer Type X in Central Iran: A New Clinicopathologic Description.

Authors:  Mehrdad Zeinalian; Mahdi Hadian; Morteza Hashemzadeh-Chaleshtori; Rasoul Salehi; Mohammad Hassan Emami
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.